Compass Pathways Plc ADR (CMPS) Stock Price, Quote & News

Company Profile

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company...

Industry: Medical Care Facilities

Sector: Healthcare

Phone: 44 716 6766461

Website: compasspathways.com

Address:

33 Broadwick Street, London, United Kingdom

RuddyRolls Jul. 19 at 11:07 PM

$CMPS $DFTX $HELP Strong point. But doesn't explain why CMPS is 4x HELP mkt cap (2x might be about right - efficacy aside, relative just to time to outcome) and DFTX is 3.5 almost 4x CMPS mkt cap. Perhaps then it appears that DFTX is appropriately priced given probable TAM in a multi-player market - and both CMPS and HELP are due to triple. Or perhaps DFTX is due to double again and the others 6x. Lets see.

2 · Reply

ROCKYGEM711 Jul. 19 at 10:46 PM

$CMPS Article well worth reading https://www.cnbc.com/2026/07/19/psychedelic-drugs-mental-health.html... Great find by our Posters!!! Just another CATALYST 4 CMPS ... Load up and be patient You could be on the Magic Mystery Ride to Profit Land. GL BULLS 😎

0 · Reply

YaKnowImRight Jul. 19 at 10:27 PM

$CMPS Word

0 · Reply

Millionaire11 Jul. 19 at 8:15 PM

$CMPS $DFTX $HELP

0 · Reply

BankOnTheFuture Jul. 19 at 7:41 PM

$CMPS Excellent post on reddit by pale-shoe3160. Commercialization timelines the big 3 People are ignoring the mechanical reality of biotech timelines on clinicaltrials.gov. A trial ending does not mean an immediate launch. You have a non-negotiable 4 to 6 month lag to clean data and package the NDA, plus a 90-day DEA rescheduling window before commercial dosing can legally start. Even if you assume a best-case scenario where competitors get a 60-day priority voucher, they are still handcuffed by their trial completion dates. Compass is finishing its rolling NDA submission right now in Q4 2026. With a voucher compressing review to 1 or 2 months, they are on track to start commercial patient dosing in the first half of 2027. >>see 1st comment for rest

1 · Reply

twiggs462 Jul. 19 at 6:47 PM

$DFTX $CMPS CNBC - The market for psychedelic drugs to treat mental health conditions gets a big buy signal https://www.cnbc.com/2026/07/19/psychedelic-drugs-mental-health.html

1 · Reply

Zeliko13 Jul. 19 at 3:15 PM

$CMPS https://www.cnbc.com/amp/2026/07/19/psychedelic-drugs-mental-health.html

2 · Reply

Millionaire11 Jul. 19 at 1:24 PM

$CMPS I am very excited for this upcoming week. This is where we start to separate and gain some momentum. Earnings updates to anticipate July 30th and NDA submission to anticipate early Q4

0 · Reply

Millionaire11 Jul. 19 at 1:37 AM

$CMPS $HELP

1 · Reply

RuddyRolls Jul. 19 at 12:41 AM

$CMPS these are the strategic facts Hold a position

0 · Reply

COMPASS Pathways PLC put volume heavy and directionally bearish

2026-07-16T10:40:21.000Z - 3 days ago

Compass Pathways’ COMP360 treatment featured in published PTSD trial

Jul 16, 2026, 6:35 AM EDT - 3 days ago

Compass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherapy

2026-07-09T13:50:15.000Z - 10 days ago

Psychedelic: Compass Pathways reports six-month data for psilocybin drug

ATAI CMND DFTX HELP

2026-07-08T13:40:54.000Z - 11 days ago

Evercore upgrades Compass Pathways to Outperform, views approval as likely

2026-07-08T13:35:14.000Z - 11 days ago

Compass Pathways upgraded to Outperform from In Line at Evercore ISI

2026-07-08T11:05:09.000Z - 11 days ago

Compass Pathways price target raised to $21 from $14 at Stifel

2026-07-07T19:50:16.000Z - 12 days ago

Wolfe Research says Compass Pathways pullback an attractive entry point

2026-07-07T19:45:11.000Z - 12 days ago

Compass Pathways announces six-month data from COMP006 trial

2026-07-07T17:50:10.000Z - 12 days ago

Compass new data validates COMP360 durability profile, says Morgan Stanley

2026-07-07T15:45:17.000Z - 12 days ago

Compass Pathways data strengthens launch prospects, says Oppenheimer

2026-07-07T13:55:32.000Z - 12 days ago

Compass Pathways study data supports benefit of second dose, says Stifel

Jul 7, 2026, 8:00 AM EDT - 12 days ago

COMPASS Pathways Transcript: Study result

Jul 7, 2026, 8:00 AM EDT - 12 days ago

COMPASS Pathways Press release: Study result

Jul 7, 2026, 8:00 AM EDT - 12 days ago

COMPASS Pathways Slides: Study result

Jul 7, 2026, 6:30 AM EDT - 12 days ago

Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile

Jul 2, 2026, 6:30 AM EDT - 17 days ago

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 26, 2026, 9:30 AM EDT - 23 days ago

A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year

DFTX

2026-06-26T11:55:16.000Z - 23 days ago

Compass Pathways price target raised to $20 from $18 at Canaccord

2026-06-24T16:15:10.000Z - 25 days ago

COMPASS Pathways PLC put volume heavy and directionally bearish

Jun 24, 2026, 7:41 AM EDT - 25 days ago

3 Companies Redefining Healthcare Innovation

CRSP VRTX

Jun 1, 2026, 10:00 AM EDT - 6 weeks ago

Why Trump Is Pushing Psychedelics To Treat Mental Illness

May 31, 2026, 8:00 AM EDT - 7 weeks ago

Why Trump reversed course to fast-track psychedelic drugs for mental healthcare

May 28, 2026, 6:30 AM EDT - 7 weeks ago

Compass Pathways Elects Kathleen Tregoning to Board of Directors

May 26, 2026, 6:30 AM EDT - 7 weeks ago

Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 2026

May 19, 2026, 10:00 AM EDT - 2 months ago

COMPASS Pathways Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 14, 2026, 6:30 AM EDT - 2 months ago

Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026

May 13, 2026, 8:00 AM EDT - 2 months ago

COMPASS Pathways Earnings Call Transcript: Q1 2026

May 13, 2026, 8:00 AM EDT - 2 months ago

COMPASS Pathways Quarterly report: Q1 2026

May 13, 2026, 8:00 AM EDT - 2 months ago

COMPASS Pathways Earnings release: Q1 2026

May 13, 2026, 8:00 AM EDT - 2 months ago

COMPASS Pathways Earnings release: Q1 2026

May 13, 2026, 7:00 AM EDT - 2 months ago

COMPASS Pathways Slides: Investor presentation

May 13, 2026, 6:30 AM EDT - 2 months ago

Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights

May 6, 2026, 6:30 AM EDT - 2 months ago

Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026

Apr 27, 2026, 11:00 AM EDT - 2 months ago

COMPASS Pathways Transcript: Needham Virtual Psychedelics Forum

Apr 24, 2026, 10:37 AM EDT - 3 months ago

Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher

Apr 21, 2026, 6:30 AM EDT - 3 months ago

Compass Pathways Collaborates with Osmind to Advance Independent Clinic Readiness for Psychedelic Treatments

Apr 20, 2026, 2:05 PM EDT - 3 months ago

How Trump's psychedelics executive order could unlock stalled cannabis reform

ATAI DFTX HELP GHRS

Apr 20, 2026, 10:45 AM EDT - 3 months ago

Psychedelic Stocks Surge After Trump Signs Order Fast-Tracking Drug Research

ATAI DFTX GHRS

Apr 20, 2026, 8:26 AM EDT - 3 months ago

Psychedelic stocks rally with Trump's support

ATAI DFTX GHRS

Apr 20, 2026, 8:18 AM EDT - 3 months ago

Trump Signs Order to Fast-Track Psychedelic Drugs. AtaiBeckley and These Other Stocks Are Soaring.

ATAI GHRS DFTX

Apr 20, 2026, 6:43 AM EDT - 3 months ago

Psychedelic drug makers rally as Trump orders FDA to expedite reviews

ATAI DFTX ENVB GHRS HELP

Apr 20, 2026, 6:30 AM EDT - 3 months ago

Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 2026

Apr 18, 2026, 4:12 PM EDT - 3 months ago

Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments

Apr 15, 2026, 8:00 AM EDT - 3 months ago

COMPASS Pathways Proxy statement: Proxy filing

Apr 14, 2026, 12:45 PM EDT - 3 months ago

COMPASS Pathways Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 14, 2026, 6:30 AM EDT - 3 months ago

Compass Pathways Announces U.S Grant Program for the Creation of Post-Approval COMP360 Provider Training

Apr 8, 2026, 6:30 AM EDT - 3 months ago

Compass Pathways to Attend Needham Virtual Healthcare Conference on April 14, 2026

Mar 24, 2026, 7:30 AM EDT - 4 months ago

Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights

Mar 24, 2026, 7:00 AM EDT - 4 months ago

COMPASS Pathways Annual report: Q4 2025

Mar 24, 2026, 7:00 AM EDT - 4 months ago

COMPASS Pathways Earnings release: Q4 2025

Mar 24, 2026, 7:00 AM EDT - 4 months ago

COMPASS Pathways Annual report: Q4 2025

Mar 18, 2026, 10:30 AM EDT - 4 months ago

COMPASS Pathways Transcript: Stifel 2026 Virtual CNS Forum

Mar 12, 2026, 6:30 AM EDT - 4 months ago

Compass Pathways to Present at Stifel 2026 Virtual CNS Forum on March 18, 2026

Mar 3, 2026, 10:30 AM EST - 4 months ago

COMPASS Pathways Transcript: TD Cowen 46th Annual Health Care Conference

Feb 26, 2026, 6:30 AM EST - 5 months ago

Compass Pathways Announces Exercise of $200 Million in Outstanding Warrants

Feb 24, 2026, 6:39 AM EST - 5 months ago

Compass Pathways to attend TD Cowen 46th Annual Healthcare Conference in Boston, MA from March 2-4, 2026

Feb 18, 2026, 8:18 PM EST - 5 months ago

Compass Pathways Announces Pricing of $150 Million Public Offering

Feb 17, 2026, 4:06 PM EST - 5 months ago

Compass Pathways Launches Proposed $150.0 Million Public Offering

Feb 17, 2026, 8:00 AM EST - 5 months ago

COMPASS Pathways Transcript: Study update

Feb 17, 2026, 8:00 AM EST - 5 months ago

COMPASS Pathways Press release: Study update

Feb 17, 2026, 8:00 AM EST - 5 months ago

COMPASS Pathways Slides: Study update

Feb 17, 2026, 6:42 AM EST - 5 months ago

Compass Pathways' depression treatment meets main goal in late‑stage study

Feb 17, 2026, 6:30 AM EST - 5 months ago

Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

Feb 16, 2026, 8:00 AM EST - 5 months ago

Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials

Feb 9, 2026, 5:01 PM EST - 5 months ago

COMPASS Pathways Plc ADR (CMPS) Price Forecast: Bullish Reversal Gains Structure

Jan 7, 2026, 10:00 AM EST - 6 months ago

COMPASS Pathways Transcript: KOL Event

Jan 7, 2026, 10:00 AM EST - 6 months ago

COMPASS Pathways Press release: KOL Event

Jan 7, 2026, 10:00 AM EST - 6 months ago

COMPASS Pathways Slides: KOL Event

Jan 7, 2026, 7:00 AM EST - 6 months ago

COMPASS Pathways Slides: Investor Presentation

Jan 7, 2026, 6:30 AM EST - 6 months ago

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD

Jan 6, 2026, 6:30 AM EST - 6 months ago

Compass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP360

Dec 9, 2025, 6:30 AM EST - 7 months ago

Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January 7, 2026, 10:00am ET

Dec 3, 2025, 1:30 PM EST - 8 months ago

COMPASS Pathways Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 10:00 AM EST - 8 months ago

COMPASS Pathways Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 20, 2025, 6:30 AM EST - 8 months ago

Compass Pathways to Participate in Two Investor Conferences in December

Nov 11, 2025, 10:40 AM EST - 8 months ago

COMPASS Pathways Transcript: Stifel 2025 Healthcare Conference

Nov 5, 2025, 6:30 AM EST - 9 months ago

Compass Pathways to Participate in Stifel 2025 Healthcare Conference

Nov 4, 2025, 9:30 AM EST - 9 months ago

COMPASS Pathways Slides: Investor Presentation

Nov 4, 2025, 8:00 AM EST - 9 months ago

COMPASS Pathways Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:00 AM EST - 9 months ago

COMPASS Pathways Quarterly report: Q3 2025

Nov 4, 2025, 8:00 AM EST - 9 months ago

COMPASS Pathways Earnings release: Q3 2025

Nov 4, 2025, 6:45 AM EST - 9 months ago

Compass Pathways to expedite launch timing of its experimental depression therapy

Nov 4, 2025, 6:30 AM EST - 9 months ago

Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months

Oct 30, 2025, 8:30 AM EDT - 9 months ago

NeuroKaire Enters into R&D Collaboration with Compass Pathways to Pioneer Precision Treatments for Depression

Oct 29, 2025, 6:30 AM EDT - 9 months ago

Compass Pathways Appoints Dr. Jeffrey Jonas to Board of Directors

Oct 28, 2025, 6:30 AM EDT - 9 months ago

Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025

Sep 2, 2025, 6:30 AM EDT - 11 months ago

Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder

Aug 27, 2025, 6:30 AM EDT - 11 months ago

Compass Pathways to Participate in Four Investor Conferences in September

Aug 12, 2025, 4:00 PM EDT - 1 year ago

COMPASS Pathways Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 5, 2025, 6:30 AM EDT - 1 year ago

Compass Pathways to Participate in Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 in Boston, MA

Jul 31, 2025, 8:00 AM EDT - 1 year ago

COMPASS Pathways Earnings Call Transcript: Q2 2025

Jul 31, 2025, 8:00 AM EDT - 1 year ago

COMPASS Pathways Earnings release: Q2 2025

Jul 31, 2025, 8:00 AM EDT - 1 year ago

COMPASS Pathways Quarterly report: Q2 2025

Jul 31, 2025, 6:30 AM EDT - 1 year ago

Compass Pathways Announces Second Quarter 2025 Financial Results and Business Highlights

Jul 29, 2025, 6:30 AM EDT - 1 year ago

Compass Pathways Appoints Justin Gover to Board of Directors

Jul 22, 2025, 6:30 AM EDT - 1 year ago

Compass Pathways to Announce Second Quarter Financial Results on July 31, 2025

Jul 10, 2025, 4:00 PM EDT - 1 year ago

Compass Pathways to Participate in HC Wainwright @Home Series Interview on July 14th, 8:00am ET

RuddyRolls Jul. 19 at 11:07 PM

2 · Reply

ROCKYGEM711 Jul. 19 at 10:46 PM

0 · Reply

YaKnowImRight Jul. 19 at 10:27 PM

$CMPS Word

0 · Reply

Millionaire11 Jul. 19 at 8:15 PM

$CMPS $DFTX $HELP

0 · Reply

BankOnTheFuture Jul. 19 at 7:41 PM

1 · Reply

twiggs462 Jul. 19 at 6:47 PM

$DFTX $CMPS CNBC - The market for psychedelic drugs to treat mental health conditions gets a big buy signal https://www.cnbc.com/2026/07/19/psychedelic-drugs-mental-health.html

1 · Reply

Zeliko13 Jul. 19 at 3:15 PM

$CMPS https://www.cnbc.com/amp/2026/07/19/psychedelic-drugs-mental-health.html

2 · Reply

Millionaire11 Jul. 19 at 1:24 PM

$CMPS I am very excited for this upcoming week. This is where we start to separate and gain some momentum. Earnings updates to anticipate July 30th and NDA submission to anticipate early Q4

0 · Reply

Millionaire11 Jul. 19 at 1:37 AM

$CMPS $HELP

1 · Reply

RuddyRolls Jul. 19 at 12:41 AM

$CMPS these are the strategic facts Hold a position

0 · Reply

Millionaire11 Jul. 18 at 11:30 PM

$CMPS $DFTX

1 · Reply

Canvasback33 Jul. 18 at 9:49 PM

$CMPS just to re-iterate, CMPS indication goal is TRD. The only player in the space is JNJ w spravato. That drug is doing roughly 2 billion in revs. The second indication compass is going for is PTSD and no other company has yet to be approved!! The hype at DFTX is wildly overblown, they had good results in MDD which is a very crowded space with SSRI’s, SNRI’s and multiple step edits and prior auths in the space. Additionally, there is a slew of Drugs that are indicated as an add on for patients not getting to remission with their MDD. PBM’s are not going to approve LSD as first, second, third, fourth possibly even fifth line of therapy. Do you really think UNH would approve it when there’s dozens of proven and more cost effective alternatives? DFTX simply played the market wisely, folks jumped in. Add a well timed cash raise when the headlines caused the pop. DFTX trials were similar to “Lykos” which used a sugar pill placebo in their trial and the as ultimately rejected by FDA.

3 · Reply

twiggs462 Jul. 18 at 2:54 PM

I personally think $ATAI sold becuase they know that cannot compete with $DFTX or $CMPS short term. Those two are going to take the spotlight and investors and $ATAI would have run out of money. I bet $LLY will take BPL-003 to market, but $ATAI would have not been able to

2 · Reply

SuperGreenToday Jul. 18 at 8:43 AM

$CMPS Share Price: $12.35 Contract Selected: Feb 19, 2027 $10 Calls Buy Zone: $2.55 – $3.15 Target Zone: $4.42 – $5.41 Potential Upside: 64% ROI Time to Expiration: 215 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

YeyYeyYey Jul. 18 at 6:21 AM

$ATAI there is no more 10x upside on this stock.. I've sold all my position yesterday, I'm not sure of the chances of getting more. Sold at 60% profit and deployed that profit into $CMPS. There is a reason they agreed on this price that we might never know.

3 · Reply

LurkerLongtime Jul. 18 at 12:49 AM

$CMPS cash awaiting deployment. 11s next week?

0 · Reply

KAE91 Jul. 17 at 11:03 PM

$CMPS I hear many talks about this stock. Anyone can give me a light up on whats good in this company?

4 · Reply

ROCKYGEM711 Jul. 17 at 10:31 PM

$CMPS GLP 1 SORRY... There are currently about 11 FDA-approved GLP-1 receptor agonist medications used to treat type 2 diabetes and obesity, with over 40 more drugs in clinical development. GL BULLS 😎 CMPS Will be the first FDA approved PTSD therapeutic treatment program in the world... Mini companies will try to replicate but we hold the keys to the kingdom.

0 · Reply

ROCKYGEM711 Jul. 17 at 10:23 PM

$CMPS IMO We definitely don't need a buyout and I understand the hype... We are the big 🐕 Dog on the porch further along than any other psychedelic company in our sector ... Will be approved by the FDA If not at the end of December then by the first part of 2027. And unlike some of our posters there are multiple trillion-dollar billion dollar pharmaceutical companies that are in competition That's what they do imagine how many of them have GP1 drugs then look back and see how many started with them this is how the game works It's competition. With that being said CMPS is the closest to The finish line. The acquisition of CMPS if we were even for sale would be much higher than ATAI. CMPS in the end will be stalwart King 👑 IMO GL BULLS 😎

0 · Reply

ROCKYGEM711 Jul. 17 at 10:02 PM

$CMPS An update on my strategy of trading CMPS If you look back at my June 25th post you'll see earnings from trading in this company with Fidelity is around $19, 000.00... My group and I feel that it's always important to take profits when available, but to always stay loaded in the company's you believe in for in just one trading Day... CMPS could open at $21 a share. We don't want to miss the train or the airplane or the rocket or whatever metaphor you want to use therefore you must always own and stash away as many shares as you can tolerate of CMPS IMO. GL BULLS 😎

0 · Reply

BankOnTheFuture Jul. 17 at 9:38 PM

$CMPS Kevin Mak's take on CMPS in light of the ATAI buyout (be sure to read part 2 in the comments): " ATAIdeal with Lily is pretty interesting, here's my opinion on the implications: First off, clearly bearish for Compass because, "Why didn't Lily buy CMPS?". They would have evaluated the two and the transaction may be interpreted as favoring ATAI's platform, although Lilly's reasoning has not been publicly disclosed. Some investors may view this as a negative signal. Directionally negative/bearish doesn't mean absolutely bearish though. The likely reasons for Lily to pick ATAI instead: They want to bet on the shorter acting drug ATAI is probably cheaper to acquire than CMPS They like the strategic profile ATAI's offerings over CMPS. (1) Makes sense as people worry about the 6-8 hour treatment regime for CMPS. I personally believe those worries are overblown. Plus, DFTX has a similar treatment regime and the market doesn’t seem too worried about that when trading at a $6B MC.

2 · Reply

BankOnTheFuture Jul. 17 at 9:18 PM

$CMPS People calling for a BO while at these price levels is driving me crazy. The price will be much higher upon FDA approval w/ management having much more leverage. Patience. We'd be leaving a lot of money on the table if CMPS were sold now.

2 · Reply

Market Cap	1.67B
Revenue (ttm)	0.00
Net Income (ttm)	-287.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.15

Volume	7,160,800
Avg Vol	4,268,914
Day's Range	N/A - N/A
Shares Out	134.95M
Stochastic %K	26%
Beta	2.47
Analysts	Strong Sell
Price Target	$23.84